

Eastern Equine Encephalitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

https://marketpublishers.com/r/EF44F59E56BCEN.html

Date: December 2022

Pages: 36

Price: US\$ 2,000.00 (Single User License)

ID: EF44F59E56BCEN

Abstracts

Eastern Equine Encephalitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis - Drugs In Development, 2022, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.



The Eastern Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Eastern Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 3 molecules, respectively.

Eastern Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Eastern Equine



Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Eastern Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Eastern Equine Encephalitis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Eastern Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand



business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction

Global Markets Direct Report Coverage

Eastern Equine Encephalitis - Overview

Eastern Equine Encephalitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Eastern Equine Encephalitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Eastern Equine Encephalitis - Companies Involved in Therapeutics Development

AlphaVax Inc

Auro Vaccines LLC

Emergent BioSolutions Inc

Innovation Pharmaceuticals Inc

Eastern Equine Encephalitis - Drug Profiles

brilacidin - Drug Profile

Product Description

Mechanism Of Action

encephalitis (trivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

equine encephalitis (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

equine encephalitis vaccine - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit Spike Glycoprotein for Alpha Virus Infections - Drug

Profile

Product Description

Mechanism Of Action

Small Molecule for Eastern Equine Encephalitis and Venezuelan Equine Encephalitis -

Eastern Equine Encephalitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2...



Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit Myd88 for Infectious Diseases, Inflammation, Septic Shock and Toxic Shock - Drug Profile

Product Description

Mechanism Of Action

TSI-GSD-104 - Drug Profile

Product Description

Mechanism Of Action

Western, Eastern and Venezuelan equine encephalitic (VLP) vaccine - Drug Profile

Product Description

Mechanism Of Action

Eastern Equine Encephalitis - Dormant Projects

Eastern Equine Encephalitis - Product Development Milestones

Featured News & Press Releases

Apr 18, 2019: UofL researcher developing drug to treat emerging encephalitis viruses

Dec 09, 2015: Profectus BioSciences Receives \$4.6 Million DOD Grant to Develop

Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development for Eastern Equine Encephalitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Eastern Equine Encephalitis - Pipeline by AlphaVax Inc, 2022

Eastern Equine Encephalitis - Pipeline by Auro Vaccines LLC, 2022

Eastern Equine Encephalitis - Pipeline by Emergent BioSolutions Inc, 2022

Eastern Equine Encephalitis - Pipeline by Innovation Pharmaceuticals Inc, 2022

Eastern Equine Encephalitis - Dormant Projects, 2022



List Of Figures

LIST OF FIGURES

Number of Products under Development for Eastern Equine Encephalitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



I would like to order

Product name: Eastern Equine Encephalitis Drugs in Development by Stages, Target, MoA, RoA,

Molecule Type and Key Players, 2022 Update

Product link: https://marketpublishers.com/r/EF44F59E56BCEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/EF44F59E56BCEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

